MCID: EWN002
MIFTS: 56

Ewing's Family of Tumors

Categories: Rare diseases, Neuronal diseases, Bone diseases, Genetic diseases

Aliases & Classifications for Ewing's Family of Tumors

MalaCards integrated aliases for Ewing's Family of Tumors:

Name: Ewing's Family of Tumors 53
Neuroectodermal Tumor, Primitive 73
Primitive Neuroectodermal Tumor 53
Ewing Family of Tumors 53
Ewing’s Tumor of Bone 53
Extraosseous Ewing’s 53
Askin’s Tumor 53

Classifications:



Summaries for Ewing's Family of Tumors

MalaCards based summary : Ewing's Family of Tumors, also known as neuroectodermal tumor, primitive, is related to sarcoma and ewing sarcoma. An important gene associated with Ewing's Family of Tumors is EWSR1 (EWS RNA Binding Protein 1), and among its related pathways/superpathways are GPCR Pathway and PEDF Induced Signaling. The drugs Lenograstim and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and lung, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Ewing's Family of Tumors

Diseases related to Ewing's Family of Tumors via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 112)
# Related Disease Score Top Affiliating Genes
1 sarcoma 30.4 EWSR1 FLI1 KIT RB1
2 ewing sarcoma 29.5 CDKN2A CSF3 EWSR1 FAS FLI1 KIT
3 extraosseous ewing's sarcoma 12.5
4 askin's tumor 12.5
5 supratentorial primitive neuroectodermal tumor 12.5
6 cerebral primitive neuroectodermal tumor 12.4
7 intracranial primitive neuroectodermal tumor 12.4
8 extraosseous ewings sarcoma-primitive neuroepithelial tumor 11.6
9 kaposiform hemangioendothelioma 10.8 FLI1 MTOR
10 bone osteosarcoma 10.7 CDK4 EWSR1
11 indolent systemic mastocytosis 10.7 KIT KITLG
12 cutaneous mastocytosis 10.6 KIT KITLG
13 kidney fibrosarcoma 10.6 EPO EWSR1
14 aggressive systemic mastocytosis 10.6 KIT KITLG
15 transient erythroblastopenia of childhood 10.6 EPO KITLG
16 uterine body mixed cancer 10.6 ERBB2 KIT
17 breast adenoid cystic carcinoma 10.6 ERBB2 KIT
18 urticaria pigmentosa 10.5 KIT KITLG
19 vulvar seborrheic keratosis 10.4 CDKN2A MTOR
20 cutaneous solitary mastocytoma 10.4 KIT KITLG
21 acquired polycythemia 10.4 EPO EPOR
22 myxoid chondrosarcoma 10.4 CDKN2B EWSR1
23 malignant mesenchymoma 10.4 CDK4 EWSR1 KIT
24 breast papillomatosis 10.4 CDKN2A ERBB2
25 connective tissue cancer 10.4 CDK4 EWSR1 KIT
26 histiocytoma 10.4 CDK4 EWSR1 KIT
27 fallopian tube endometrioid adenocarcinoma 10.3 CDKN2A ERBB2
28 bartholin's gland benign neoplasm 10.3 CDKN2A MTOR
29 renal cell carcinoma, papillary, 1 10.3 ERBB2 KIT MTOR
30 erythrocytosis, familial, 2 10.3 EPO EPOR
31 neonatal anemia 10.3 EPO EPOR
32 infiltrating angiolipoma 10.3 CDK4 CDKN2A
33 vulval paget's disease 10.3 CDKN2A ERBB2
34 spindle cell liposarcoma 10.3 CDK4 KIT
35 kidney benign neoplasm 10.3 KIT MTOR
36 primary polycythemia 10.3 EPO EPOR
37 adenoid basal cell carcinoma 10.2 CDKN2A KIT
38 luminal breast carcinoma 10.2 ERBB2 MTOR
39 vulva adenocarcinoma 10.2 CDKN2A ERBB2
40 skin sarcoma 10.2 CDK4 CDKN2B EWSR1
41 rhabdomyosarcoma 10.2
42 acute erythroid leukemia 10.2 EPO EPOR FLI1
43 doxorubicin induced cardiomyopathy 10.2 CSF3 EPOR
44 acral lentiginous melanoma 10.2 CDKN2A KIT
45 oral leukoplakia 10.1 CDKN2A ERBB2
46 polycythemia 10.1 EPO EPOR KITLG
47 ischemic fasciitis 10.1 CDK4 CDKN2A
48 spindle cell lipoma 10.1 CDK4 RB1
49 tenosynovial giant cell tumor 10.1 CDKN2A CDKN2B
50 liposarcoma 10.1 CDK4 CDKN2A EWSR1

Graphical network of the top 20 diseases related to Ewing's Family of Tumors:



Diseases related to Ewing's Family of Tumors

Symptoms & Phenotypes for Ewing's Family of Tumors

GenomeRNAi Phenotypes related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

26 (show all 30)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.17 KIT
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.17 MTOR EWSR1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.17 MTOR
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.17 CDK4
5 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.17 CDK4
6 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.17 EWSR1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.17 EWSR1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-140 10.17 EWSR1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.17 EWSR1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.17 KIT EWSR1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.17 KIT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.17 MTOR
13 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.17 EWSR1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.17 KIT
15 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.17 EWSR1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.17 CDK4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.17 KIT
18 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.17 KIT CDK4 MTOR EWSR1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.17 CDK4
20 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.17 EWSR1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.17 MTOR
22 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.17 EWSR1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.17 CDK4 KIT MTOR
24 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.17 KIT
25 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.17 KIT EWSR1
26 Decreased substrate adherent cell growth GR00193-A-1 9.7 KIT
27 Decreased substrate adherent cell growth GR00193-A-2 9.7 CDK4 KIT MTOR
28 Decreased substrate adherent cell growth GR00193-A-3 9.7 CDK4
29 Decreased substrate adherent cell growth GR00193-A-4 9.7 CDK4 KIT
30 Increased transferrin (TF) endocytosis GR00363-A 9.32 FLI1 KIT CDK4 CDKN2A CDKN2B EPO

MGI Mouse Phenotypes related to Ewing's Family of Tumors:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.38 ERBB2 EPO EPOR FAS FLI1 KITLG
2 cardiovascular system MP:0005385 10.35 ERBB2 EPO EPOR FAS FLI1 KITLG
3 hematopoietic system MP:0005397 10.35 EPOR FAS FLI1 KITLG KIT CDKN2A
4 immune system MP:0005387 10.33 EPOR FAS FLI1 KITLG KIT CDKN2A
5 homeostasis/metabolism MP:0005376 10.3 ERBB2 EPO EPOR FAS KIT KITLG
6 embryo MP:0005380 10.29 EPO EPOR ERBB2 FLI1 KITLG KIT
7 endocrine/exocrine gland MP:0005379 10.28 ERBB2 FAS FLI1 KITLG KIT CDKN2B
8 growth/size/body region MP:0005378 10.27 ERBB2 EPOR FAS KIT FLI1 CDK4
9 mortality/aging MP:0010768 10.27 ERBB2 EPO EPOR FAS KIT FLI1
10 integument MP:0010771 10.24 ERBB2 EPO FAS KITLG KIT CDKN2A
11 liver/biliary system MP:0005370 10.16 EPO EPOR FAS FLI1 KITLG KIT
12 digestive/alimentary MP:0005381 10.14 ERBB2 FAS KIT KITLG CDK4 CDKN2A
13 nervous system MP:0003631 10.13 ERBB2 EPOR FAS KIT FLI1 KITLG
14 neoplasm MP:0002006 10.11 FAS ERBB2 FLI1 KITLG KIT CDKN2A
15 muscle MP:0005369 10.08 ERBB2 EPO KIT FLI1 CDKN2A CDK4
16 limbs/digits/tail MP:0005371 10 EPO ERBB2 FAS KIT RB1 KITLG
17 normal MP:0002873 9.97 ERBB2 EPO EPOR FAS KIT CDK4
18 no phenotypic analysis MP:0003012 9.88 EPOR KIT CDKN2B CDKN2A RB1 MTOR
19 pigmentation MP:0001186 9.8 FAS KITLG KIT CDKN2A CDK4 RB1
20 renal/urinary system MP:0005367 9.8 FAS KIT CDKN2B CSF3 CDK4 RB1
21 reproductive system MP:0005389 9.76 ERBB2 FAS KIT KITLG CDK4 CDKN2B
22 respiratory system MP:0005388 9.56 ERBB2 EPO EPOR FAS KIT CDKN2A
23 skeleton MP:0005390 9.23 EPO ERBB2 FAS KIT CDKN2A RB1

Drugs & Therapeutics for Ewing's Family of Tumors

Drugs for Ewing's Family of Tumors (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 920)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
2
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
3
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
4
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
5
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-23-7 5754
6
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
7
Carboplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 41575-94-4 10339178 498142 38904
8
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 4342-03-4 5351166
9
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106-60-5 137
10
Mesna Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3375-50-6 598
11
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
12
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
13
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85622-93-1 5394
14
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
15
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 52-24-4 5453
16
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
17
Sunitinib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 341031-54-7, 557795-19-4 5329102
18
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 124-94-7 31307
19
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 99011-02-6 57469
20
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
21
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
22
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 83150-76-9 383414 6400441
23
Dabrafenib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1195765-45-7 44462760 44516822
24
Palbociclib Approved, Investigational Phase 4,Phase 2,Phase 1 571190-30-2 11431660 5005498 5330286
25
Trametinib Approved Phase 4,Phase 3,Phase 1,Phase 2 871700-17-3 11707110
26
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
27
nivolumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 946414-94-4
28
Aldesleukin Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 85898-30-2, 110942-02-4
29
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 59917-39-4, 53643-48-4 40839
30
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
31
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 38916-34-6, 51110-01-1 53481605
32
Dasatinib Approved, Investigational Phase 4,Phase 1,Phase 2 302962-49-8 3062316
33
Doxazosin Approved Phase 4,Phase 3 74191-85-8 3157
34
Cortisone acetate Approved, Investigational Phase 4 1950-04-4, 50-04-4 5745
35 Piracetam Approved, Investigational Phase 4,Phase 2 7491-74-9
36
Diazoxide Approved Phase 4,Phase 3,Phase 2 364-98-7 3019
37
Etanercept Approved, Investigational Phase 4,Phase 2 185243-69-0
38
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 99-66-1 3121
39
Bortezomib Approved, Investigational Phase 4,Phase 2,Phase 1 179324-69-7 387447 93860
40
Phenoxybenzamine Approved Phase 4,Phase 3 59-96-1 4768
41
Gefitinib Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 184475-35-2 123631
42
Itraconazole Approved, Investigational Phase 4,Phase 1 84625-61-6 55283
43
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1994-09-7, 94-09-7 2337
44 lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 108736-35-2
45
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 51-43-4 5816
46
Vorinostat Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 149647-78-9 5311
47
Olaparib Approved Phase 4,Phase 2,Phase 1 763113-22-0 23725625
48
Ramucirumab Approved, Investigational Phase 4,Phase 2,Phase 1 947687-13-0
49
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 53608-75-6
50
Racepinephrine Approved Phase 4,Phase 2,Phase 1,Not Applicable 329-65-7 838

Interventional clinical trials:

(show top 50) (show all 4973)
# Name Status NCT ID Phase Drugs
1 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Unknown status NCT02759718 Phase 4
2 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
3 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4 Cisplatin, Vindesine, Dacarbazine (drugs)
4 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
5 Stereotactic Body Radiotherapy for Head and Neck Tumors Unknown status NCT01344356 Phase 4
6 Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) Completed NCT02277587 Phase 4 Plenadren;Conventional glucocorticoid therapy
7 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
8 Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors Completed NCT01595009 Phase 4 RAD001
9 Somatuline Autogel Preference and Health Economy Study Completed NCT00681187 Phase 4 lanreotide (Autogel formulation)
10 Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients Completed NCT02075606 Phase 4 lanreotide acetate
11 CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma Completed NCT02319486 Phase 4 carboplatin periocular injection;CEV chemotherapy
12 Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab Completed NCT01515189 Phase 4
13 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
14 Phenoxybenzamine Versus Doxazosin in PCC Patients Completed NCT01379898 Phase 4 Phenoxybenzamine;Doxazosin
15 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
16 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
17 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Completed NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
18 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4 Temozolomide
19 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
20 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4 Imiquimod
21 Dolutegravir and Darunavir Evaluation in Adults Failing Therapy Recruiting NCT03017872 Phase 4 NRTIs;Dolutegravir;Darunavir;Ritonavir
22 HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Recruiting NCT02875314 Phase 4 Induction;Single Cycle Intensive Chemotherapy;Tandem 3 Cycle Intensive Chemotherapy
23 A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide Recruiting NCT03289741 Phase 4 Octreotide;LAR Lanreotide
24 Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET Recruiting NCT03083210 Phase 4 Lanreotide
25 Nonfunctional Pancreatic NET and PET Imaging Recruiting NCT02621541 Phase 4
26 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
27 Seizure Treatment in Glioma Recruiting NCT03048084 Phase 4 Levetiracetam;Valproic Acid
28 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma Recruiting NCT02451488 Phase 4 GM-CSF
29 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
30 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Recruiting NCT02379754 Phase 4 Gentamicins
31 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
32 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Recruiting NCT02520635 Phase 4 supra-early TEMODAL® chemotherapy;standard TEMODAL® chemotherapy
33 Dabrafenib and/or Trametinib Rollover Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
34 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
35 Radiolabeled Molecules for Medullary Thyroid Cancer Recruiting NCT01915485 Phase 4
36 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
37 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4 sunitinib
38 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Active, not recruiting NCT02626065 Phase 4 Nivolumab
39 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Active, not recruiting NCT02379000 Phase 4 Triamcinolone Acetonide
40 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Active, not recruiting NCT02068196 Phase 4 Ipilimumab
41 An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma Active, not recruiting NCT01898585 Phase 4 Zelboraf
42 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Not yet recruiting NCT02933333 Phase 4
43 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4 Standard therapy or clinical trial;Matched targeted therapy;Trametinib and / or supportive care
44 Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4 Temozolomide
45 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
46 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
47 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
48 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
49 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
50 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate

Search NIH Clinical Center for Ewing's Family of Tumors

Genetic Tests for Ewing's Family of Tumors

Anatomical Context for Ewing's Family of Tumors

MalaCards organs/tissues related to Ewing's Family of Tumors:

41
Brain, T Cells, Lung, Bone, Liver, Thyroid, Kidney

Publications for Ewing's Family of Tumors

Articles related to Ewing's Family of Tumors:

(show top 50) (show all 764)
# Title Authors Year
1
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor in the Adrenal Gland of a Child. ( 29891750 )
2018
2
Thyroid dysfunction in patients with childhood-onset medulloblastoma or primitive neuroectodermal tumor. ( 29969880 )
2018
3
Integrated bioinformatic analysis unveils significant genes and pathways in the pathogenesis of supratentorial primitive neuroectodermal tumor. ( 29670360 )
2018
4
Rare Ileal Ewing Sarcoma/Primitive Neuroectodermal Tumor on 18F-FDG PET/CT. ( 28806254 )
2017
5
Primary Ewing Sarcoma / Primitive Neuroectodermal Tumor of the Kidney: A Clinicopathologic Study of 23 Cases. ( 28429277 )
2017
6
Malignant glioma-primitive neuroectodermal tumor recurring as PNET-like only subdural collection: Case report. ( 29119041 )
2017
7
Estrogen and soy isoflavonoids decrease sensitivity of medulloblastoma and central nervous system primitive neuroectodermal tumor cells to chemotherapeutic cytotoxicity. ( 28877739 )
2017
8
Primary Pure Endometrial Primitive Neuroectodermal Tumors with <i>EWSR1</i> Gene Rearrangement: Report of 2 Cases. ( 28801375 )
2017
9
Outcome for children treated for medulloblastoma and supratentorial primitive neuroectodermal tumor (CNS-PNET) - a retrospective analysis spanning 40 years of treatment. ( 28325133 )
2017
10
Primary Ewing's sarcoma/primitive neuroectodermal tumor of the ileum: case report of a 16-year-old Chinese female and literature review. ( 28472972 )
2017
11
A peripheral primitive neuroectodermal tumor in the larynx: A case report and literature review. ( 26893703 )
2016
12
Primary Ewing sarcoma/primitive neuroectodermal tumor in the adrenal gland. ( 27197626 )
2016
13
Pediatric Primitive Neuroectodermal Tumors of the Central Nervous System Differentially Express Granzyme Inhibitors. ( 26963506 )
2016
14
Management of Primitive Neuroectodermal Tumor of the Kidney with Inferior Vena Cava Thrombus. ( 26989372 )
2016
15
Cervicomedullary intramedullary peripheral primitive neuroectodermal tumor with intratumoral bleed: Report of one case and review of literature. ( 27217659 )
2016
16
Malignant glioma with primitive neuroectodermal tumor-like component (MG-PNET): novel microarray findings in a pediatric patient. ( 27781423 )
2016
17
Peripheral Primitive Neuroectodermal Tumor and Neurofibromatosis Type 1 in an Adolescent Male. ( 26828586 )
2016
18
Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: A Rare and Lethal Entity. ( 26927724 )
2016
19
Primary Ewing's Sarcoma/Primitive Neuroectodermal Tumor of Kidney with Caval Involvement in a Pregnant Woman. ( 27035149 )
2016
20
Cerebellopontine angle primitive neuroectodermal tumor mimicking trigeminal schwannoma. ( 26862446 )
2016
21
Development of CNS-type Primitive Neuroectodermal Tumor in Metastatic Testicular Mixed Germ Cell Tumor. ( 27169016 )
2016
22
Primitive Neuroectodermal Tumor of the Stomach: A Case Report. ( 27006299 )
2016
23
Primary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Stomach. ( 27920700 )
2016
24
Primitive Neuroectodermal Tumor with Glioblastoma Multiforme Components in an Adult: A Collision Tumor. ( 26918224 )
2016
25
Primary Primitive Neuroectodermal Tumor Arising from an Ovarian Mature Cystic Teratoma in a 12-Year-Old Girl: A Case Report. ( 27919713 )
2016
26
Treatment outcome and patterns of failure in patients of non-pineal supratentorial primitive neuroectodermal tumor: review of literature and clinical experience form a regional cancer center in north India. ( 25990846 )
2015
27
Endobronchial Primitive Neuroectodermal Tumor With Pneumothorax Ex Vacuo. ( 26434446 )
2015
28
Primary primitive neuroectodermal tumor arising in the mesentery and ileocecum: A report of three cases and review of the literature. ( 25780425 )
2015
29
Suprasellar Primitive Neuroectodermal Tumor in an Adult. ( 26517622 )
2015
30
Cyclin D1 is a useful marker for soft tissue Ewing's sarcoma/peripheral Primitive Neuroectodermal Tumor in children and adolescents: A comparative immunohistochemical study with rhabdomyosarcoma. ( 25765111 )
2015
31
Central-type primitive neuroectodermal tumor of the uterus: Case report of remission of stage IV disease using adjuvant cisplatin/etoposide/bevacizumab chemotherapy and review of the literature. ( 26793768 )
2015
32
Primary renal primitive neuroectodermal tumor: A rare presentation. ( 25766349 )
2015
33
Extraskeletal Ewing's sarcoma/primitive neuroectodermal tumor of the mediastinum: Significant response to chemoradiotherapy. ( 25621030 )
2015
34
Primitive neuroectodermal tumor/ewing sarcoma presenting with pulmonary nodular lesions. ( 25705534 )
2015
35
Ewing's Sarcoma/Primitive Neuroectodermal Tumor of the Uterine Corpus. ( 25812660 )
2015
36
Pancreatic peripheral primitive neuroectodermal tumor diagnosed by endoscopic ultrasound. ( 25603505 )
2015
37
Uterine primitive neuroectodermal tumor. ( 25841950 )
2015
38
Correction: Tissue elasticity regulated tumor gene expression: implication for diagnostic biomarkers of primitive neuroectodermal tumor. ( 25992612 )
2015
39
The postirradiation incidence of cavernous angioma is higher in patients with childhood pineoblastoma or primitive neuroectodermal tumors than medulloblastoma. ( 25690449 )
2015
40
Primitive Neuroectodermal Tumor of the Pancreas: A Case Report and Review of the Literature. ( 26101685 )
2015
41
Rapidly progressive primitive neuroectodermal tumor of the prostate: A case report and review of the literature. ( 25624891 )
2015
42
Peripheral primitive neuroectodermal tumor of the kidney in a 51-year-old female following breast cancer: A case report and review of the literature. ( 25435942 )
2015
43
A primary primitive neuroectodermal tumor arising from left subclavian vein and extending along left brachiocephalic vein and superior vena cava into right atrium. ( 25725277 )
2015
44
Peripheral primitive neuroectodermal tumor of chest wall in young adult. ( 25798010 )
2015
45
A peripheral primitive neuroectodermal tumor originating from the pancreas: a case report and review of the literature. ( 26380804 )
2015
46
Feasibility and efficacy of salvage radiotherapy with concurrent weekly topotecan in recurrent primitive neuroectodermal tumor. ( 26837963 )
2015
47
A Case of Renal Primitive Neuroectodermal Tumor Confirmed by Fluorescence in situ Hybridization. ( 26034481 )
2015
48
Novel treatment of a central type, primitive neuroectodermal tumor of the ovary with postoperative pediatric medulloblastoma chemotherapy regimen: A case report and review of the literature. ( 26425724 )
2015
49
Heavy Metal Bioaccumulation in an Atypical Primitive Neuroectodermal Tumor of the Abdominal Wall. ( 26270725 )
2015
50
Tissue elasticity regulated tumor gene expression: implication for diagnostic biomarkers of primitive neuroectodermal tumor. ( 25774514 )
2015

Variations for Ewing's Family of Tumors

Expression for Ewing's Family of Tumors

Search GEO for disease gene expression data for Ewing's Family of Tumors.

Pathways for Ewing's Family of Tumors

Pathways related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

(show all 47)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.62 CDK4 CDKN2A CDKN2B EPOR ERBB2 KIT
2
Show member pathways
13.59 CSF3 EPO EPOR ERBB2 FAS KIT
3
Show member pathways
13.58 CDK4 CDKN2A CDKN2B CSF3 EPOR ERBB2
4
Show member pathways
13.41 EPO EPOR ERBB2 KIT KITLG MTOR
5
Show member pathways
13.3 CSF3 EPOR ERBB2 FAS KIT KITLG
6
Show member pathways
13.04 CDK4 CDKN2A CDKN2B EPO MTOR RB1
7
Show member pathways
12.9 CDK4 CDKN2A CDKN2B KIT KITLG RB1
8
Show member pathways
12.84 EPO EPOR FAS KIT KITLG
9
Show member pathways
12.73 CDK4 CDKN2A ERBB2 KIT MTOR RB1
10
Show member pathways
12.64 ERBB2 KIT KITLG MTOR
11
Show member pathways
12.62 CDK4 CDKN2A CDKN2B ERBB2 MTOR RB1
12
Show member pathways
12.56 CSF3 EPO EPOR MTOR
13
Show member pathways
12.5 CDK4 FAS MTOR RB1
14
Show member pathways
12.49 CDK4 CDKN2A CDKN2B RB1
15 12.48 FAS FLI1 KIT KITLG
16
Show member pathways
12.48 CDK4 CSF3 EPO EPOR ERBB2 FAS
17
Show member pathways
12.47 CDK4 CDKN2A CDKN2B ERBB2 KIT MTOR
18 12.35 CDK4 CDKN2A CDKN2B RB1
19
Show member pathways
12.3 CDK4 CDKN2A FAS RB1
20
Show member pathways
12.27 CDK4 CDKN2A CDKN2B RB1
21 12.25 CDK4 CDKN2A CDKN2B KITLG RB1
22 12.21 CDK4 CDKN2A CDKN2B RB1
23
Show member pathways
12.13 CDK4 CDKN2A CDKN2B RB1
24
Show member pathways
12.08 EPO EPOR KIT KITLG
25 12.08 CDK4 CDKN2A CDKN2B EPO EPOR ERBB2
26 12.06 CDK4 MTOR RB1
27 12.03 ERBB2 KIT KITLG
28 12.01 CDK4 CDKN2A CDKN2B MTOR RB1
29
Show member pathways
11.94 CDK4 ERBB2 MTOR RB1
30 11.9 CSF3 EPO KIT KITLG
31 11.87 CDKN2A MTOR RB1
32 11.87 CDK4 CDKN2A MTOR RB1
33 11.84 EPO ERBB2 MTOR
34 11.81 EPO EPOR MTOR
35 11.8 CDK4 CDKN2B RB1
36 11.68 CDKN2A ERBB2 FAS
37 11.65 CDK4 MTOR RB1
38 11.62 ERBB2 KIT MTOR
39 11.6 CDK4 CDKN2A ERBB2 RB1
40 11.54 CSF3 EPO EPOR KIT KITLG
41 11.48 CDKN2A FAS RB1
42 11.45 EPO KIT KITLG
43 11.41 CDK4 CDKN2B RB1
44 11.3 CSF3 EPO FLI1 KITLG
45 11.23 CDK4 CDKN2A CDKN2B
46 11.03 CDKN2A RB1
47 10.88 KIT KITLG

GO Terms for Ewing's Family of Tumors

Biological processes related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.91 CDKN2A ERBB2 KIT MTOR
2 negative regulation of apoptotic process GO:0043066 9.91 EPO ERBB2 FAS KIT KITLG
3 positive regulation of cell proliferation GO:0008284 9.88 CDK4 CSF3 EPO KIT KITLG
4 phosphorylation GO:0016310 9.8 CDK4 CDKN2A CDKN2B ERBB2 KIT MTOR
5 positive regulation of MAPK cascade GO:0043410 9.79 ERBB2 FAS KIT
6 G1/S transition of mitotic cell cycle GO:0000082 9.74 CDK4 CDKN2A RB1
7 phosphatidylinositol phosphorylation GO:0046854 9.73 ERBB2 KIT KITLG
8 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.71 CSF3 KITLG MTOR
9 positive regulation of translation GO:0045727 9.67 CDK4 ERBB2 MTOR
10 positive regulation of Ras protein signal transduction GO:0046579 9.61 EPO KITLG
11 positive regulation of MAP kinase activity GO:0043406 9.61 ERBB2 KIT KITLG
12 negative regulation of phosphorylation GO:0042326 9.6 CDKN2A CDKN2B
13 embryonic hemopoiesis GO:0035162 9.59 KIT KITLG
14 megakaryocyte development GO:0035855 9.58 FLI1 KIT
15 response to hyperoxia GO:0055093 9.58 CDK4 EPO
16 cell cycle arrest GO:0007050 9.56 CDKN2A CDKN2B MTOR RB1
17 positive regulation of transcription by RNA polymerase III GO:0045945 9.55 ERBB2 MTOR
18 positive regulation of protein kinase B signaling GO:0051897 9.55 CSF3 ERBB2 KIT KITLG MTOR
19 somatic stem cell division GO:0048103 9.52 CDKN2A KIT
20 ectopic germ cell programmed cell death GO:0035234 9.46 KIT KITLG
21 negative regulation of immature T cell proliferation in thymus GO:0033088 9.37 CDKN2A ERBB2
22 negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031658 9.13 CDK4 CDKN2A CDKN2B
23 erythropoietin-mediated signaling pathway GO:0038162 8.8 EPO EPOR KIT
24 signal transduction GO:0007165 10.01 CDK4 EPO EPOR ERBB2 FAS KIT

Molecular functions related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.71 CDK4 ERBB2 KIT MTOR
2 identical protein binding GO:0042802 9.63 EPOR ERBB2 EWSR1 FAS MTOR RB1
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.54 ERBB2 KIT KITLG
4 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.32 CDKN2A CDKN2B
5 obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.26 ERBB2 KIT
6 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.13 ERBB2 KIT KITLG
7 kinase activity GO:0016301 9.1 CDK4 CDKN2A CDKN2B ERBB2 KIT MTOR
8 protein binding GO:0005515 10.25 CDK4 CDKN2A CDKN2B EPO EPOR ERBB2

Sources for Ewing's Family of Tumors

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....